The Inhibition of 5-lipoxygenase by RG 6866

Overview

Journal Agents Actions

Specialty Pharmacology

Date 1989 Nov 1

PMID 2596372

Authors

G W Carnathan

D M Sweeney

J J Travis

R J Gordon

C A Sutherland

N Jariwala

M Clearfield

S ORourke

F C Huang

R G Van Inwegen

Affiliations

Soon will be listed here.

Abstract

The generation of leukotrienes C4, D4 and E4 from arachidonic acid is dependent upon the activity of 5-lipoxygenase (5-LOX). The effects of RG 6866 (N-methyl-4-benzyloxyphenylacetohydroxamic acid) on the activity of guinea pig 5-LOX in vitro and in vivo were determined in the present study. The generation of 5-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE) from arachidonic acid by isolated guinea pig peritoneal polymorphonuclear (PMN) cells was inhibited by incubation with RG 6866 (IC50 = 0.20 microM). A similar effect (IC50 = 0.23 microM) was observed when 5-HETE production was measured in a supernatant fraction from PMNs. Additionally, the compound did not inhibit 3H-LTD4 binding to guinea pig membranes. In actively sensitized guinea pigs pretreated with indomethacin, propranolol and pyrilamine, RG 6866 inhibited antigen-induced systemic anaphylaxis and LTD4-dependent bronchoconstriction in a dose-dependent manner following oral administration. In the pulmonary anaphylaxis model, significant (p less than 0.05) inhibition of the mortality was observed within 30 min and maintained through four hours after treatment with RG 6866 (50 mg/kg i.g.). Finally, orally administered RG 6866 inhibited the formation of LTC4 in these animals with an ED50 = 24.0 mg/kg. These findings indicate that RG 6866 is an inhibitor of 5-LOX both in vitro and in vivo.

References

Hand J, Schwalm S, Lewis A . Antagonism of antigen-induced contraction of isolated guinea-pig trachea by 5-lipoxygenase inhibitors. Int Arch Allergy Appl Immunol. 1986; 79(1):8-13. DOI: 10.1159/000233934. View

Salonen R . Actions of bronchodilator drugs, glucocorticoid, and their combinations on airways in rats and guinea pigs. Acta Pharmacol Toxicol (Copenh). 1985; 57 Suppl 3:1-38. View

Weichman B, Muccitelli R, OSBORN R, HOLDEN D, Gleason J, Wasserman M . In vitro and in vivo mechanisms of leukotriene-mediated bronchoconstriction in the guinea pig. J Pharmacol Exp Ther. 1982; 222(1):202-8. View

Hanna C, Bach M, Pare P, Schellenberg R . Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro. Nature. 1981; 290(5804):343-4. DOI: 10.1038/290343a0. View

Andersson P, BERGSTRAND H . Antigen-induced bronchial anaphylaxis in actively sensitized guinea-pigs: effect of long-term treatment with sodium cromoglycate and aminophylline. Br J Pharmacol. 1981; 74(3):601-9. PMC: 2071757. DOI: 10.1111/j.1476-5381.1981.tb10470.x. View

Snyder D, Giles R, Keith R, Yee Y, Krell R . In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther. 1987; 243(2):548-56. View

Simmons P, Salmon J, Moncada S . The release of leukotriene B4 during experimental inflammation. Biochem Pharmacol. 1983; 32(8):1353-9. DOI: 10.1016/0006-2952(83)90446-x. View

Carnathan G, SANNER J, Thompson J, Prusa C, Miyano M . Antagonism of the in vivo and in vitro effects of leukotriene D4 by SC-39070 in guinea pigs. Agents Actions. 1987; 20(1-2):124-32. DOI: 10.1007/BF01965634. View

McFarlane C, Hamel R, Ford-Hutchinson A . Effects of a 5-lipoxygenase inhibitor (L-651,392) on primary and late pulmonary responses to ascaris antigen in the squirrel monkey. Agents Actions. 1987; 22(1-2):63-8. DOI: 10.1007/BF01968818. View

10.

Van Inwegen R, Khandwala A, Gordon R, Sonnino P, Coutts S, Jolly S . REV 5901: an orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile. J Pharmacol Exp Ther. 1987; 241(1):117-24. View

11.

Fleisch J, Rinkema L, Haisch K, Goodson T, Ho P, Marshall W . LY171883, 1-less than 2-hydroxy-3-propyl-4-less than 4-(1H-tetrazol-5-yl) butoxy greater than phenyl greater than ethanone, an orally active leukotriene D4 antagonist. J Pharmacol Exp Ther. 1985; 233(1):148-57. View

12.

Smith M, Ford-Hutchinson A, Bray M . Leukotriene B: a potential mediator of inflammation. J Pharm Pharmacol. 1980; 32(7):517-8. DOI: 10.1111/j.2042-7158.1980.tb12985.x. View

13.

Van Inwegen R, NUSS G, Carnathan G . Antagonism of peptidoleukotrienes and inhibition of systemic anaphylaxis by RG 12525 in guinea pigs. Life Sci. 1989; 44(12):799-807. DOI: 10.1016/0024-3205(89)90377-9. View

14.

Hay D, Muccitelli R, Tucker S, Wilson K, Gleason J, Hall R . Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. J Pharmacol Exp Ther. 1987; 243(2):474-81. View

15.

Griswold D, Marshall P, WEBB E, Godfrey R, Newton Jr J, Dimartino M . SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem Pharmacol. 1987; 36(20):3463-70. DOI: 10.1016/0006-2952(87)90327-3. View

16.

Yoshimoto T, Yokoyama C, Ochi K, Yamamoto S, Maki Y, Ashida Y . 2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis. Biochim Biophys Acta. 1982; 713(2):470-3. View

17.

Turner N, Dollery C . Release of arachidonic acid metabolites and histamine from sensitized guinea-pig lung following antigen challenge. Br J Pharmacol. 1988; 93(4):751-8. PMC: 1853874. DOI: 10.1111/j.1476-5381.1988.tb11459.x. View

18.

Chang J, Skowronek M, Cherney M, Lewis A . Differential effects of putative lipoxygenase inhibitors on arachidonic acid metabolism in cell-free and intact cell preparations. Inflammation. 1984; 8(2):143-55. DOI: 10.1007/BF00916090. View